August 20 – 21, 2019

Day One
Tuesday 21 August, 2018

Day Two
Wednesday 22 August, 2018

Chair’s Opening Remarks

  • Fernando Martinez Chief, Pulmonary & Critical Care Medicine, Weill Cornell Medical College

IPF: Recent Advances & the Future Landscape

Keynote: IPF: Where are we now?

  • Fernando Martinez Chief, Pulmonary & Critical Care Medicine, Weill Cornell Medical College


  • Highlighting progress from IPF Summit 2017 including advancement of the standardization of imaging
  • Reviewing the IPF drug development landscape
  • Outlining outcomes for the 2nd IPF Summit from the outset

Beyond Bleomycin: More Confidently Utilizing Preclinical Models

Beyond Bleomycin: The Nintedanib Experience

  • Gerald Nabozny Executive Director Inflammation, Immunology & Respiratory Disease Research, Boehringer Ingelheim


  • Exploring the mode of action of Nintedanib using a broad and diverse set of cellular models
  • Discussing in vivo models with diverse triggers
  • Sharing what was learned about Nintedanib activity in preclinical models

Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF  ield and establish meaningful business relationships to pursue for the rest of the conference.

Morning Refreshments

Targeting Translational Failings Through Use of Non-Invasive Imaging & Biomarkers

Introduction to 4Dx Technology

  • Neeraj Vij Program Director, Clinical Development, 4Dx


  • Outlining the 4Dx technology: quantitative imaging of ventilation
  • Comparing 4Dx quantitative imaging with existing imaging modalities
  • Sharing the validation of the technology

Leveraging Biomarker Data for Dose Selection


  • Outlining biomarker selection in IPF and associations with the TGFβ pathway
  • Showcasing preclinical data outlining doses to inhibit fibrosis in animal models
  • Analyzing human studies at 8 weeks for extent of TGFβ inhibition and rationale behind dose selection

Be Better then Ashcroft Scoring: Quantitative, Reproducible Assessment of IPF by Automated Digital Image Analysis

  • Yvon Jule Chief Scientific Officer, Biocellvia


  • Revealing how digital image analysis overcomes the  limitations and subjective bias of Ashcroft scoring by quantitatively assessing morphometric readouts
  • Evaluating automated analysis bypasses any manual annotation, thus saving time and generating accurate and reproducible results
  • Exploring how, in IPF animal models, we can visualize the expression of collagen and quantification of fibrosis based on the digital images of hole lung sections

Lunch & Networking

Next Generation of IPF Clinical Trials: Evaluating Trial Design

Regional Disease Progression & Quantification of Interstitial Lung Diseases Using Functional Respiratory Imaging


  • Outlining Functional Respiratory Imaging for use in IPF
  • Demonstrating the value of quantitative CT imaging in IPF drug development
  • Highlighting imaging use to show regional disease state and expression
  • Discussing imaging associated biomarkers within IPF

A Closer Look at FVC


  • Overcoming visit-to-visit variability in FVC is a challenge for investigators and clinicians: is there a better way forward?

IPF: An Orphan Disease with Successful Phase 3 Trials!

  • John Moran Chief Medical Officer, Prometic Biosciences


  • Overcoming the challenges of designing a phase 3 trial with limited prior trial data in an orphan disease
  • Good news: For IPF we have a legion of data from pivotal phase 3 studies
  • Bad news: For IPF there are two approved drugs

Transforming IPF Clinical Trials Through Direct Patient Engagement

  • Komathi Stem Founder & Chief Executive Officer , monARC Bionetworks

Afternoon Break & Networking

Rho-Associated Coiled-Coil Kinase 2 (ROCK2) Inhibition in IPF

  • John Ryan Executive Vice President & Chief Medical Officer, Kadmon


  • Outlining therapeutic potential of ROCK inhibition in regulating pro-fibrotic processes
  • Sharing the ongoing clinical development of KD025 in IPF

Taking Advantage of Human Genetics for Preclinical & Clinical Decisions

Genetic & Genomic Considerations in IPF Clinical Trials

  • David Schwartz Professor of Medicine & Immunology, University of Colorado-Denver


  • Outlining IPF as a heterogeneous disease caused by multiple gene variants
  • Demonstrating the distinct clinical course for each type of IPF
  • Showing how drug trials should control the disease heterogeneity in IPF

Panel Discussion: Precision Medicine in IPF – Using Genetics to Inform Patient Stratification Decisions for Clinical Trials

  • Timothy Blackwell Professor of Medicine , Vanderbilt University Medical Center
  • Fernando Martinez Chief, Pulmonary & Critical Care Medicine, Weill Cornell Medical College
  • David Schwartz Professor of Medicine & Immunology, University of Colorado-Denver


Shared insights from key opinion leaders with a focus on:

  • Outlining what is known about inherited genetic factors and their influence in the development of IPF
  • Hypothesizing how future studies will characterize patient phenotypes and how they will influence trial design and outcome
  • Understanding the influence of genetics and precision therapeutics on clinical decision-making regarding IPF diagnosis and treatment

Chair’s Closing Remarks

  • Fernando Martinez Chief, Pulmonary & Critical Care Medicine, Weill Cornell Medical College

Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on.
The Poster Session allows you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.